Evidence map›Paper›PMID 40406370›Full record

ArticleOpen forum infectious diseases2025

Epidemiology of Rubella Virus in a Fragile and Conflict-affected Setting - A Retrospective Analysis of 11 Years Case-based Data in South Sudan.

Sylvester Maleghemi, Atem Nathan Anyuon, Isaac Michael Zingbondo, George Awzenio Legge, Melisachew Adane Ferede, Patrick Freeman Eweh, Evans Mokaya, Patience Musanhu, Humphrey Karamagi, Sarah Wanyoike and 3 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sylvester MaleghemiVaccine-Preventable Diseases Programme World Health Organization Country Office, Juba, South Sudan.ORCID https://orcid.org/0000-0001-8078-7242
Atem Nathan AnyuonExpanded Programme on Immunization Ministry of Health, Juba, Republic of South Sudan.
Isaac Michael ZingbondoExpanded Programme on Immunization Ministry of Health, Juba, Republic of South Sudan.
George Awzenio LeggeExpanded Programme on Immunization Ministry of Health, Juba, Republic of South Sudan.
Melisachew Adane FeredeVaccine-Preventable Diseases Programme World Health Organization Country Office, Juba, South Sudan.
Patrick Freeman EwehVaccine-Preventable Diseases Programme World Health Organization Country Office, Juba, South Sudan.
Evans MokayaCountry Programmes Delivery Gavi Alliance, Geneva, Switzerland.
Patience MusanhuCountry Programmes Delivery Gavi Alliance, Geneva, Switzerland.
Humphrey KaramagiVaccine-Preventable Diseases Programme World Health Organization Country Office, Juba, South Sudan.
Sarah WanyoikeVaccine-Preventable Diseases Programme World Health Organization Intercountry Support Team, Harare, Zimbabwe.
Diana Chang BlancDepartment of Immunization, Vaccines and Biologicals (IVB) World Health Organization, Geneva, Switzerland.
Olushayo Oluseun OluOffice of the Director of Programme Management World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.
Ayesheshem Ademe TegegneVaccine-Preventable Diseases Programme World Health Organization Country Office, Juba, South Sudan.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Introduction: Since establishing routine immunization services in what was then known as Sudan in 1974, South Sudan has not yet introduced the rubella-containing vaccine into its national immunization schedule. This study aims to assess the burden of rubella infection within the existing measles case-based surveillance framework to provide evidence supporting advocacy for introducing the rubella-containing vaccine into the national immunization program. Methods: This study conducted a retrospective descriptive analysis of rubella infection using measles case-based surveillance data from 2013 to 2023. Data were analyzed with descriptive statistics and logistic regression using Epi Info, version 7. Results: During the study period, 17,987 suspected measles cases were reported, with 4944 serum samples collected. Of these, 2083 (42.1%) were positive for measles immunoglobulin M antibodies. Among 2861 samples that tested negative or indeterminate for measles, 678 (23.7%) tested positive for rubella immunoglobulin M antibodies. The study observed a significant increase in rubella positivity rates from 1.6% in 2014 to 34.4% in 2020. Logistic regression analysis showed that rubella infection was significantly more likely among children aged 5-9 years (odds ratio [OR] = 2.234; 95% confidence interval [CI]; 1.468-3.473, Conclusions: The study identified a high prevalence of rubella among young children, particularly those aged 1-9 years and in urban areas, highlighting the need for targeted vaccination strategies. These findings strongly support introducing the rubella vaccine into the national immunization program.

Indexed as

conflict-affected settingsrubella surveillancerubella virusSouth Sudanvaccination

Identifiers

PMID40406370
PMCPMC12095998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.